This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Eli Lilly & Company

Drug Names(s): AIR hGH

Description: AIR hGH-GHD is an inhaled formulation of human growth hormone using Alkermes' AIR technology, which utilizes drug particles that can be delivered using small, simple inhalers. AIR technology accommodates high drug doses, provides systemic delivery as well as local or targeted delivery to the lung, offers rapid onset of action and the potential for prolonged release.

Deal Structure: In February 2000, Eli Lilly and Company and Alkermes signed an agreement to develop an inhaled formulation of human growth hormone based on the Alkermes AIR pulmonary drug delivery system. Under the terms of the agreement, Alkermes will receive certain initial fees, funding for research and milestone payments. Alkermes will also receive royalty payments based on product sales. In exchange, Lilly will receive exclusive worldwide rights to products resulting from the collaboration.Alkermes will be responsible for manufacturing products commercialized as a result of the agreement, while Lilly will be responsible for conducting clinical trials, securing regulatory approvals and marketing on a worldwidebasis.

Partners: Alkermes plc

AIR hGH News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug